Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG2000 in advanced CLL and AML
NCT02034227Phase 2Terminated
- Sponsor
- Spirogen
- Start
- Apr 2012
- Primary completion
- Jun 2014
- Countries
- 1
01
Overview
A Phase 2 trial of SJG-136 in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), sponsored by Spirogen. Started Apr 2012; status: terminated.
02
Drugs
SJG-136
03
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02034227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034227.